NASDAQ:ERNA - Nasdaq - US1140822099 - Common Stock - Currency: USD
1.9
+0.02 (+1.06%)
The current stock price of ERNA is 1.9 USD. In the past month the price decreased by -44.93%. In the past year, price decreased by -93.08%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.19 | 329.95B | ||
AMGN | AMGEN INC | 13.44 | 150.08B | ||
GILD | GILEAD SCIENCES INC | 13.9 | 133.87B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 113.87B | ||
REGN | REGENERON PHARMACEUTICALS | 11.76 | 56.25B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 41.50B | ||
ARGX | ARGENX SE - ADR | 97.4 | 34.20B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.5 | 27.53B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.52B | ||
NTRA | NATERA INC | N/A | 22.96B | ||
BIIB | BIOGEN INC | 8.02 | 18.60B | ||
INSM | INSMED INC | N/A | 18.53B |
Eterna Therapeutics, Inc. engages in the provision of cell engineering therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 6 full-time employees. The firm is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The firm seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The firm is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.
ERNEXA THERAPEUTICS INC
1035 Cambridge Street, Suite 18A
Cambridge MASSACHUSETTS US
Employees: 6
Phone: 16177986700
The current stock price of ERNA is 1.9 USD. The price increased by 1.06% in the last trading session.
The exchange symbol of ERNEXA THERAPEUTICS INC is ERNA and it is listed on the Nasdaq exchange.
ERNA stock is listed on the Nasdaq exchange.
ERNEXA THERAPEUTICS INC (ERNA) has a market capitalization of 118.48M USD. This makes ERNA a Micro Cap stock.
ERNEXA THERAPEUTICS INC (ERNA) currently has 6 employees.
ERNEXA THERAPEUTICS INC (ERNA) has a resistance level at 2.15. Check the full technical report for a detailed analysis of ERNA support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ERNA does not pay a dividend.
ERNEXA THERAPEUTICS INC (ERNA) will report earnings on 2025-08-11.
ERNEXA THERAPEUTICS INC (ERNA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.25).
ChartMill assigns a fundamental rating of 1 / 10 to ERNA. ERNA may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months ERNA reported a non-GAAP Earnings per Share(EPS) of -6.25. The EPS decreased by -47.05% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -911.44% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 43% to ERNA. The Buy consensus is the average rating of analysts ratings from 6 analysts.